Chapter
4: Acute Myeloid Leukemias (AML)
·
AML with
multilineage dysplasia
·
AML and MDS,
therapy-related
·
AML not otherwise
categorized
·
Acute leukemia of
ambiguous lineage
AML with
recurrent genetic abnormalities
·
t(8;21)(q22;q22)(AML/ETO)
·
inv(16) or t(16;16)(p13q22); (CBFβ/MYH11)
·
t(15;17)(q22;q21)
·
11q23(MLL)
AML with multilineage dysplasia
·
AML plus
dysplasia
·
Dysplasia:
>50% of cells of 2 or more myeloid lines in a pre-treatment specimen
·
May occur de novo
or following MDS or MDS/MPD
·
Mainly in elderly
and rare in children
·
Often severe
pancytopenia
·
Dysgranulopoiesis,
dyserythropoiesis, dysmegakaryopoiesis
·
Blasts positive
for CD34 and pan-myeloid markers (CD13 and CD33)
·
Frequently:
aberrant expression of CD56 and CD7
·
Increased
incidence of multidrug resistance glycoprotein: MDR-1
·
Genetics : similar to MDS
o Often:
-7/del(7q), -5/del(5q), +8, +9, +11, del(11q), del(12p), -18, +19,
del(20q), +21
o Less often:
t(2;11), t(1;7), 3q21 and 3q26
o
t(3;21)(q21;q26):
usually therapy related, or associated with CML as a 2nd
event at blastic crisis
o
t(3;5)(q25;q34)
is associated with mutilineage dysplasia but no thrombocytosis
·
Prognosis:
multilineage dysplasia has adverse effect on remission
Therapy-Related
AML/MDS
·
After cytotoxic
chemotherapy and/or radiation therapy
·
Two types
o
Alkylating agent
and radiation therapy related
o
Topoisomerase II
inhibitor related
Alkylating Agent/Radiation Therapy Related AML/MDS
·
Occur 5-6 years
after initiation of treatment
·
Range: 10-192
months
·
Risk related to age
and cumulative dosage
·
Mutagenic effects
of ionizing radiation and alkylating agents
·
Two-thirds of
cases present as MDS
·
One-third of
cases present as overt AML with MDS features
·
All myeloid cell
lines affected
·
Dyserythropoiesis
·
Ringed
sideroblasts in 60% of cases (one-third in excess of 15% of erythroids)
·
Hypogranulation
and nuclear hypolobation in granulocytes
·
Dysplastic
megakaryocytes, increased in 25% of cases
·
Basophils
increased in 25% of cases
·
Auer rods in a
minority of cases
·
Bone marrow
biopsy: hypercellular in 50%, normocellular in 25%, hypocellular in 25%, fibrosis
in 15%
·
Types of AML: M2,
M4, M5, M6, M7
·
Immunophenotype
o
Blasts often
CD34+, CD33+, CD13+, frequent aberrant expression of CD56+ and CD7+
o
Increased
incidence of MDR-1 expression in blasts
·
Genetics
o
Increased
cytogenetic abnormalities
o
Similar to de novo MDS, RCMD, RAEB
o
Unbalanced
translocations
o
Deletions of
chromosomes 5 and 7 (long arms)
o
Chromosomes 1, 4,
12, 14, 18
o
Complex
chromosomal abnormalities
·
Prognosis: Poor
response to therapy, poor survival
Topoisomerase II Inhibitor Related AML/MDS
·
Epipodophyllotoxins
and related compounds that target DNA-Topoisomerase II, examples etoposide and
teniposide, also anthracyclines, such as doxorubicin and 4-epi-doxorubicin
·
All ages
·
Shorter latency:
12-130 months (median: 33-34 months)
·
Latency can be
less than 6 months
·
Usually presents
as overt AML without a previous MDS phase
·
Significant
monocytic component
·
Most are acute
monoblastic or myelomonocytic, occasionally acute promyelocytic leukemia or acute
megakaryoblastic leukemia
·
Bone marrow
usually hypercellular
·
Acute
lymphoblastic leukemia also possible, usually
associated with t(4;11)(q21;q23) chromosome abnormality
·
Genetics:
o
Usually balanced
translocation involving 11q23 (MLL gene) and primarily t(9;11), t(11;19), and
t(6;11)
o
Others t(8;21),
t(3;21), inv(16), t(8;16), and t(6;9)
o
t(4;11)(q21;q23) (associated with ALL)
o t(15;17)(q22;p21)
(APL)
·
Prognosis: good
initial response to therapy, but relapses frequent and survival variable (especially
poor with 11q23)
AML
not otherwise categorized
·
Cases that do not
fulfill criteria for inclusion in:
o
AML with
recurrent genetic abnormalities
o
AML with
multilineage dysplasia
o
AML and MDS,
therapy-related
·
Basis for
subclassification in this category
o
Morphology
o
Cytochemistry
o
Degree of
maturation
§
Defining criterion for AML is ³20%
myeloblasts in PB or BM (differential for 500 cells in BM, or 200 leukocytes in
PB). PB smear and BM aspirate provide the major criteria required for
categorization. BM biopsy is for assessment of marrow cellularity in pre- and
post-therapy, also for diagnosis of hypocellular acute leukemia cases and
leukemia associated with fibrosis
§
Blast equivalents
·
Promyelocytes in
APL
·
Promonocytes in
AML with monocytic differentiation
o
Megakaryoblasts
·
Recommendations
for classification are applicable only to specimens obtained prior to
chemotherapy.
·
Subtypes
o
Acute
myeloblastic leukemia, minimally differentiated (M0)
o
Acute
myeloblastic leukemia without maturation (M1)
o
Acute
myeloblastic leukemia with maturation (M2)
o
Acute
myelomonocytic leukemia (M4)
o
Acute monoblastic
leukemia (M5a) and Acute monocytic leukemia (M5b)
o
Acute erythroid
leukemia (M6)
o
Acute
megakaryoblastic leukemia (M7)
o
Acute basophilic
leukemia
o
Acute panmyelosis
with myelofibrosis
o
Myeloid sarcoma
Acute myeloblastic leukemia, minimally differentiated
(M0)
·
Definition
o
Acute leukemia
with no evidence of myeloid differentiation by
§
Morphology, and Light microscopic cytochemistry
o
Myeloid nature of
blasts demonstrated by
§
Immunologic markers, and/or
§
Ultrastructural studies
o
Immunophenotyping
studies essential to rule out ALL
·
Epidemiology
o
5% of cases of
AML
o
Mostly adults
·
Clinical
o
Present with
marrow failure: anemia, neutropenia, thrombocytopenia
o
May have
leukocytosis with increased blasts
·
Blasts
o
Medium size
o
Round or slightly
indented nuclei
o
Dispersed nuclear
chromatin
o
1 or 2 nucleoli
o
Agranular
cytoplasm
o
Myeloperoxidase
(MPO): negative
o
Sudan Black B
(SBB): negative
o
Naphthol ASD
chloroacetate esterase: negative
o
Alpha naphthyl butyrate
esterase: negative or weak reactivity
·
BM: markedly
hypercellular with poorly differentiated blasts
·
Ultrastructural
studies: may demonstrate MPO activity
·
Blast
immunophenotype: positive for
o
One or more
pan-myeloid antigen
§
CD13, CD33, CD117 (all cases)
o
Primitive
hematopoietic associated antigens
§
CD34, CD38 and HLA-DR (most cases)
o
TdT (1/3 of cases
or more)
o
Antigens associated
with, but not specific for, lymphoid differentiation
§
CD7, CD2, CD19 (frequently)
·
Blast
immunophenotype: negative for
o
B and T lymphoid
restricted antibodies
§
cCD3, cC79a, and cCD22
o
MPO often
negative (may be positive in a few blasts)
o
Antigens associated
with myelomonocytic maturation
§
CD11b, CD15, CD14, CD65
·
Genetics
o
No unique
abnormality
o Most common: complex karyotypes, +13, +8, +4, -7
·
Prognosis is poor:
lower remission rate, more frequent early relapse, shorter survival
Acute myeloblastic leukemia without maturation (M1)
·
Definition
o
Characterized by
a high percentage of BM blasts without significant evidence of maturation to
more mature neutrophils
o
Blasts ³90% of non-erythroid cells
o
The myeloid
nature of blasts is demonstrated by: MPO or SBB positivity (>3%) and/or Auer rods
·
Epidemiology
o
10% of cases of
AML
o
Adults (median
age 46 y/o), but can occur at any age
·
Clinical
o
Present with
marrow failure: anemia, neutropenia, thrombocytopenia
o
May have
leukocytosis with markedly increased blasts
·
Blasts
o
Typical
myeloblasts with azurophilic granules, and /or Auer rods
o
Lymphoblast-like
with no granules
·
MPO and SBB
variably positive (but always positive in ³3% of blasts)
·
BM
o
Usually markedly
hypercellular
o
Blasts in BM
sections may react with antibodies to MPO, Lysozyme, CD117, and/or CD34
·
Differential
diagnosis
o
ALL, if
§
Blasts have no granules
§
Low percentage of MPO positivity
§
Resolution: TdT, MPO, SBB
o
AML with
maturation (M2), with a high percentage of blasts
§
Resolution: % promyelocytes and more mature
neutrophils more than 10% of nucleated cells
o
Acute monoblastic
leukemia (M5a)
§
Resolution: NSE, MPO, SBB
o
Acute
megakaryoblastic leukemia (M7)
§
Resolution: CD41, CD61, MPO, SBB
·
Blast
immunophenotype: positive for
o
Two or more
myelomonocytic antigens (CD13, CD33, CD117) and/or
o
MPO
o
CD34
·
Blast
immunophenotype: negative for
o
Markers associated
with monocytic maturation
§
CD11b, CD14
o
Lymphoid antigens
§
CD3, CD20, CD79a
·
Genetics
o
No specific
chromosomal abnormalities
·
Prognosis
o
Aggressive course
(particularly with hyperleukocytosis)
Acute Myeloblastic Leukemia with Maturation (M2)
·
At least 20%
blasts in bone marrow or blood (but less than 90%)
·
Granulocytic
elements (promyelocytes through PMNs) at least 10% of non-erythroid cells
·
Monocytic
elements <20% of non-erythroid cells
·
30-45% of all
AMLs
·
All ages, 20%
< 25 years, 40% are 60 years or older
·
Anemia, thrombocytopenia,
neutropenia
·
Variable number
of blasts in blood
·
Bone marrow
hypercellular
·
Blasts with or
without granules
·
Auer rods
frequent
·
Various degrees
of dysplasia
·
Eosinophils and
basophils may be increased
·
Differential
Diagnoses
o
RAEB (if blast
numbers are at lower limit)
o
AML without
maturation (if blast numbers are at upper limit)
o
AMML (when
monocytes are increased)
·
Immunophenotype
o
CD13+, CD33+,
CD15+
o
Often CD34+,
CD117+, HLA-DR+
·
Genetics
o
del(12)(p11-p13)
associated with increased basophils
o
t(6;9)(p23;q34)
(DEK/CAN fusion gene), associated with poor prognosis
o
t(8;16)(p11;p13)
associated with erythrophagocytosis
·
Responds
frequently to aggressive therapy
Acute promyelocytic leukemia (M3)
·
Definition: AML
with t(15;17)(q22;q21);(PML/RARa)
·
Variants: hypergranular and microgranular (hypogranular)
types
·
Epidemiology: 5-8% of AML, age: mid life
·
Clinical features:
o Typical
(hypergranular) and microgranular APL: DIC
o Microgranular:
high WBC with numerous promyelocytes
·
Morphology
and cytochemistry
o Hypergranular
APL: kidney-shaped, bilobed, dense large granules,Faggot cells (cells with bundles
of Auer rods), MPO: strongly +, NSE: + in 25% of cases
o Microgranular
(hypogranular): bilobed, promyelocytes, MPO(strongly)
·
BM Bx: hypercellular, cells with abundant
cytoplasm and convoluted nuclei
·
Immunophenotype:
o CD33,
homogenous and bright
o CD13,
heterogeneous
o CD34(-)
o CD15(-)
o CD2(+)CD9(+)
co-expression
·
PML Ab stain: nuclear multigranular vs speckled
in normal promyelocytes or
blasts of other AMLs
·
Features
of APL with variant translocations
o t(11;17)(q23;q21),
PLZF on 11
§
No Auer rods, regular nuclei, pseudo
Pelger-Huet cells
§
Resistant to ATRA
o t(5;17)(q23;q12),
NPM on 5
§
rare, atypical APL, no Auer rods, responds to
ATRA
o t(11;17)(q13;q21),
NuMA on 11
·
Cell of origin:
myeloid stem cell to granulocytic lineage
·
Prognosis:
favorable, use of retinoids in combinatorial protocols with anthracycline-based
chemotherapy for front line treatment currently results in long-term survival
and potential cure in at least 60% of newly diagnosed patients.
Acute Myelomonocytic Leukemia (M4)
·
Blasts at least
20%
·
Monocytic cells
at least 20% of cells in bone marrow
·
Elevated
circulating monocytes (usually above 5 x 109/L)
·
15-25% of all
AMLs
·
Median age: 50
years
·
Male-to-female
ratio 1.4:1
·
Anemia, thrombocytopenia,
fever, fatigue
·
Morphology:
o
Monoblasts
round nuclei, lacy chromatin, one or more prominent nuclei, abundant basophilic
cytoplasm, pseudopods, some granules and
vacuoles.
o
Promonocytes
blast equivalent, more irregular nucleus, more granules
o
MPO + (at least
3% of blasts)
o
Monocytic
elements: non-specific esterase +
o
Double staining
for MPO and esterase can be present
·
Differential
Diagnoses
o
AML with
maturation
o
Acute monocytic
leukemia
·
Immunophenotype
o
CD13+, CD33+
(myeloid)
o
CD14+, CD4+,
CD11b+, CD11c+, CD64+, CD36+, lysozyme+
·
Genetics
o
Non-specific
o
Specific
abnormalities are under AML with recurrent genetic abnormalities, such as (inv)16:
eosinophils with immature granule (purple-violet in color), obscuring cell morphology
o
11q23
·
Frequently
responds to aggressive therapy
·
Variable survival
rates
Acute Monoblastic/Monocytic Leukemia (M5)
·
At least 80% of bone
marrow cells are monoblasts, promonocytes, and monocytes
·
Promonocytes are
blast equivalents
·
Neutrophil elements
<20%
·
Acute monoblastic
leukemia (M5a) at least 80% monoblasts
·
Acute monocytic
leukemia (M5b) less than 80% monoblasts
·
M5a: 5-8% of all
AMLs, usually young individuals (but may occur at any age), in infancy often
with 11q23, extramedullary lesions possible
·
M5b: 3-6% of all
AMLs, adults with median age of 49 ,years, male-to-female ratio 1.8:1
·
Clinical
features: bleeding disorders most common presentation, cutaneous and gingival
infiltration, CNS involvement, extramedullary masses
·
Non-specific
esterase activity strongly positive (but weak or even negative in 20%)
·
MPO negative
(promonocytes may have some positivity)
·
DDx for Acute
Monoblastic Leukemia
o
AML, minimally
differentiated
o
AML, without
maturation
o
Acute
megakaryoblastic leukemia
o
Soft tissue
sarcomas
o
Lymphomas
·
DDx for Acute
Monocytic Leukemia
o
AMML
o
Microgranular
variant of acute promyelocytic leukemia (MPO strongly +)
·
Immunophenotype
o
CD13+, CD33+,
CD117+,
o
CD14+, CD4+,
CD11b+, CD11c+, CD64+, CD68+, CD36+, lysozyme+
o
CD34 usually
negative
·
Genetics
o
Abnormalities of
11q23 with acute monoblastic leukemia (included in AML with recurrent genetic
abnormalities)
o
t(8;16)(p11;p13)
associated with acute monocytic leukemia, erythrophagocytosis by leukemic cells
·
Prognosis: both
acute monoblastic and monocytic leukemia follow aggressive course
Acute Erythroid Leukemias (M6)
·
Definition: acute
leukemias characterized by predominant erythroid population
·
Two subtypes
based on presence or absence of a significant myeloid component
·
Erythroleukemia
(erythroid/myeloid)
o
>50% erythroid precursors of nucleated cells in BM
o
>20% myeloblasts of non-erythroid cells in BM
·
Pure erythroid
leukemia
o
>80% immature erythroid of nucleated cells in BM
o
No significant
myeloblastic component
·
Epidemiology
o
Adults
o
5-6% of AML
o
Pure erythroid
leukemia: rare, at any age
o
Some CML can
undergo erythroblastic transformation
·
Clinical features
o
Profound anemia
·
Normoblastemia
·
May evolve from
MDS, either RAEB or RA-MLD with or without RS
·
Morphology
o BM
§
Hypercellular
§
Megakaryocytic
dysplasia
o Erythroid
§
All stages present
§
Frequent
dysplasia: megaloblastoid nuclei, multinucleated forms, cytoplasmic vacuoles
o Myeloid:
blasts similar to those in AML M1 or M2
·
Erythroleukemia
(erythroid/myeloid)
o
Iron stain: ringed
sideroblasts
o
PAS: globular or
diffuse cytoplasmic staining
o
MPO and SBB: may
be positive for myeloblasts
·
Pure Erythroid
leukemia
o
Morphology: medium
to large-sized erythroblasts with round nuclei, fine chromatin and one or more
nucleoli, deeply basophilic cytoplasm, and often vacuolated
o
Cytochemistry:
§
PAS positive vacuoles
§
MPO negative
§
Alpha-naphthyl acetate esterase and acid
phosphatase positive
·
Differential
diagnosis of erythroleukemia (erythroid/myeloid)
o
RAEB
o
AML with
maturation and increased erythroid precursors
o
AML with
multilineage dysplasia
·
Differential
diagnosis of pure erythroid leukemia
o
Megaloblastic
anemia due to vitamin B12 or folate deficiency
§
Response to vitamins
§
Less dysplasia
§
Hypersegmented neutrophils
o
Other AML;
especially megakaryoblastic
§
Concurrent erythroid-megakaryocytic involvement
o
ALL, lymphoma
§
Lymphoid markers
·
Immunopheotype of
erythroleukemia (erythroid/myeloid)
o Erythroid
o
MPO negative
o
Glycophorin A,
hemoglobin A positive
·
Myeloblasts
o CD13, CD33,
CD117, MPO, +/-CD34, +/- HLA-DR
·
Immunophenotype of
pure erythroid leukemia
o
Glycophorin A and
hemoglobin A in more differentiated forms
o
Immature forms
negative for glycophorin Ap
o
Positive for
carbonic anhydrase 1, Gero antibody (against the Gerbich blood group)
o CD36
(may also be expressed in monocytes and megakaryocytes)
o
Megakaryocytic
antigens CD41 and CD61: typically negative or partially expressed
o
Negative for MPO,
HLA-DR, CD34
·
Genetics
o
No specific
chromosome abnormality
o
Complex
karyotypes common with chromosomes 5 and 7 frequently affected
·
Cell of Origin
o
Erythroleukemia
(erythroid/myeloid):multipotent stem-cell with wide myeloid
potential
o
Pure erythroid
leukemia: primitive stem cell with some degree of commitment to the erythroid
lineage
·
Prognosis and
predictive factors
o
Erythroleukemia
(erythroid/myeloid)
§
Aggressive clinical course
§
May evolve to a prominent myeloblast picture
·
Pure erythroid
leukemia
o Rapid
clinical course
Acute megakaryoblastic leukemia (M7)
·
Definition: acute
leukemia in which >50% of the blasts are megakaryocytic lineage
·
Epidemiology
o
Adults and
children
o
Relatively
uncommon, 3-5% of AML
·
Clinical features
o
Cytopenias, often
thrombocytopenia, sometimes thrombocytosis
o
Dysplastic
features in neutrophils and platelets
o
Organomegaly in
children with t(1;22) often with prominent abdominal masses
o Bone
lytic lesions
·
Associated with mediastinal
germ cell tumors in young adult males
·
Morphology of megakaryoblast:
medium to large size, round, slightly irregular nucleus, fine reticular
chromatin, one to three nucleoli, basophilic cytoplasm, agranular, bleb or
pseudopod formation. Blasts may occasionally be small resembling lymphoblasts
·
Morphology/histopathology
o
BM
§
Variable: uniform population of poorly
differentiated blasts or mixture of poorly differentiated blasts and maturing dysplastic
megakaryocytes
§
Variable reticulin fibrosis that may yield a dry
tap
o
PB: micromegakaryocytes
(small cells, one or two round nuclei, condensed chromatin, mature cytoplasm, not to be counted
as blasts), megakaryoblastic fragments, dysplastic large platelets, hypogranular
neutrophils
·
Genetics: not
specific except for
o
t(1;22)(p13;q13)
§
Infants (less than 1 y/o)
§
Stromal pattern of infiltration mimicking
metastatic tumor
·
Cytochemistry
o
SSB and MPO
negative
o
PAS and Acid Phosphatase
positive, and punctuate NSE
·
EM
o
Peroxidase
activity confined to the nuclear membranes and ER with Platelet Peroxidase (PPO)
reaction
·
Differential
diagnosis
o
Minimally
differentiated AML
o
Acute panmyelosis
with myelofibrosis
o
ALL
o
Pure erythroid
leukemia
o
Blastic
transformation of CML or CIMF
§
History of chronic phase
§
Splenomegaly common
§
Red cell abnormalities in CIMF
§
BCR/ABL in CML
o
Metastatic tumors
in children
§
Alveolar rhabdomyosarcoma
§
Neuroblastoma
·
Immunophenotype
o
Platelet glycoproteins
§
CD41, CD61 (cytoplasmic more sensitive)
§
Factor VIII
§
CD42 (mature platelets) less frequent
o
Myeloid markers
§
CD13 and CD33 positive
§
MPO, CD34, CD45 and HLA-DR negative
o
CD36
o
Lymphoid: aberrant
CD7
·
Genetics
o
No unique
chromosomal abnormality in adults
o
Inv(3)(q21;q26)
found in other leukemias
o
t(1;22)(p13;q13)
§
Infants (less than 1 y/o)
§
Stromal pattern of infiltration mimicking
metastatic tumor
o
Young men with
germ cell tumors i(12p)
·
Cell of origin: precursor
committed to the megakaryocytic lineage and possibly erythroid lineage
·
Prognosis: poor,
particularly in infants with t(1;22)
Variant of AML (M7): Acute myeloid leukemia/transient
myeloproliferative disorder in Down Syndrome
·
Down Syndrome: increased
predisposition to acute leukemia, particularly AML (M7)
Acute
myeloid leukemia/transient myeloproliferative disorder in Down Syndrome:
usually with spontaneous remission
·
Clinical features
o
Manifests in
neonatal period
o
Marked
leukocytosis, PB blasts usually >30%, often >50%
o
May have
prominent extramedullary involvement
·
Morphology
o
Blasts
§
12-15 υm round to slightly irregular nuclei
§
Moderate amounts of basophilic cytoplasm, cytoplasmic
blebs, coarse azurophilic granules
o
Promegakayocytes
and micromegakaryocytes frequent
o
Dyserythropoiesis
common
o
Dysgranulopoiesis
minimal
o
Increased
basophils
·
Cytochemistry
o
Blasts
§
MPO, SBB, TdT negative
§
May have scattered, granular PAS positivity
·
EM
o
Variable number
of blasts with platelet peroxidase reactivity
·
Genetics
o
Trisomy 21
o
Additional clonal
abnormalities
§
Trisomy 8 most frequent
§
No t(1;22)
o
FISH shows
cytogenetic abnormalities in megakaryocytic and erythroid precursors
o
Molecular studies:
clonality by X-chromosome linked polymorphism analysis
·
Cell of origin: myeloid
precursor cell with potential for megakaryocytic and erythroid differentiation
·
Prognosis: remits
spontaneously in one to three months, recurrence and 2nd remission or
persistent disease may occur
Acute basophilic leukemia
·
Definition
o
Acute myeloid
leukemia with primary differentiation to basophils
o
Some may
represent blast transformation in undetected CML
·
Epidemiology
o
< 1% of AML
·
Morphology
o
Blasts
§
Medium sized with high N/C ratio, oval or
bilobed nucleus, dispersed chromatin, one to three prominent nucleoli
§
Moderately basophilic cytoplasm
·
Basophilic
granules
·
Vacuolation
o
Mature basophils
sparse
o
Dyserythropoiesis
·
Cytochemistry
o
Metachromatic
positivity with toluidine blue
o
Diffuse pattern
with acid phosphatase
o
Some with PAS
positivity
o
No SBB, MPO or
NSE by light microscopy
·
EM
o
Granules with
electron-dense particulate substance, characteristic of basophils or mast cells
o
Peroxidase
activity in nuclear membrane ER and granules
·
BM
o
Diffuse
replacement by blasts
o
Increased
basophil precursors
o
Mast cell
differentiation with distinct morphology: oval nucleus, elongated cytoplasm, close
to trabeculae, prominent reticulin fibrosis
·
Differential
diagnosis
o
Blast crisis of
CML
o
AML subtypes with
basophilia
§
AML M2 with 12p or t(6;9)
§
Acute eosinophilic leukemia
§
ALL with prominent coarse granules
·
Immunophenotype
of blasts
o Myeloid
markers CD13, CD33
o Early
hematopoietic markers CD34 and HLA-DR
o Lymphoid
markers: CD9 (usually) and TdT (sometimes)
·
Genetics
o
No consistent
chromosomal abnormality
o
12p or t(6;9) not
identified
o
A few cases with
de-novo Ph chromosome positive acute leukemia t(9;22)(q34;q11)
·
Cell of origin: early
myeloid cell committed to basophilic lineage
·
Prognosis: generally
associated with poor prognosis
Acute panmyelosis with myelofibrosis
·
Definition: acute
panmyeloid proliferation with accompanying fibrosis
·
Epidemiology
o
Rare form of AML,
primarily adults
o
Can be de-novo or secondary to Alkylating-agent
chemotherapy and/or radiation
·
Clinical features
o
Constitutional
symptoms: weakness, fatigue
o
Marked
pancytopenia
o
Minimal or no
splenomegaly
o
Rapidly
progressive
·
Morphology
o
PB
§
Marked pancytopenia
§
RBC with little poikilocytosis or anisocytosis,
variable macrocytes, rare normoblasts
§
Occasional immature neutrophils including blasts
§
Dysplastic changes in myeloid cells frequent
§
Atypical platelets
o
BM
§
Hypercellular, variable degrees of hyperplasia
of erythroid granulocytic and megakaryocytic lineages
§
Foci of immature cells, including blasts
throughout
§
Foci of late stage erythroid cells prominent
§
Megakaryocytes conspicuous, small and large with
dysplastic features including hypolobation
§
Eosinophilic cytoplasm: PAS +, + antibodies to
FVIII, and CD61 +
§
Variable reticulin fibrosis (aspiration
frequently unsuccessful)
·
Differential
diagnosis
o
Acute
megakaryoblastic leukemia
o
Other acute
leukemia with marrow fibrosis (AML with multilineage dysplasia and fibrosis)
o
Metastatic tumor
with desmoplasia
o
CIMF: immature
cells not prominent, megakaryocytic characteristics, splenomegaly
·
Immunophenotype
o
Phenotypic
heterogeneity
o
Blasts: myeloid
antigens CD13, CD33, CD117 and MPO
o
Some proportion
of immature cells expressing erythroid or megakaryocytic antigens
·
Genetics: complex
abnormalities involving chromosomes 5 and/or 7
·
Cell of origin: myeloid
hematopoietic stem cell (fibroblast proliferation is only epiphenomenon)
·
Prognosis: poor
response to chemotherapy and short survival
Myeloid sarcoma
·
Definition
o
Tumor mass of
myeloblasts or immature myeloid cells occurring in an extramedullary site or in
bone
o
May precede or
occur concurrently with acute or chronic myeloid leukemias, MPDs or MDSs
o
Initial
manifestation of relapse in previously treated AML in remission
·
Sites of
involvement
o
Subperiosteal
bone of skull, paranasal sinuses, sternum, ribs, vertebrae and pelvis
o
Lymph nodes
o
Skin
·
Clinical features:
can be de-novo or concurrently
or preceding AML (may precede AML by months to years)
·
Differential
diagnosis
o
Non-Hodgkin lymphomas
(lymphoblastic, Burkitt, large-cell lymphomas)
o
Small round cell
tumors (neuroblastoma, rhabdomyosarcoma, Ewings/PNET and medulloblastoma)
o High
index of suspicion in undifferentiated tumors to avoid missing myeloid sarcoma
·
Immunophenotype
o
Myeloblasts: chloracetate
esterase, CD13, CD33, CD117, MPO, CD43
o
Monoblasts: CD14,
CD116, CD11c, lysozyme, CD68, CD43
·
If a tumor is
CD43+ and CD3-, then MPO, lysozyme, CD61 should be pursued
·
Genetics
o
Association with
AML with maturation and t(8;21)(q22;q22), AMML Eo with inv(16)(p13q22) or
t(16;16)(p13q22)
o
11q23 in
monoblastic sarcoma
·
Cell of origin: primitive
myeloid hematopoietic cell
·
Prognosis
o
Myeloid sarcoma
in a setting of MDS or MPD is equivalent to blast transformation
o
Myeloid sarcoma
does not generally change the prognosis of the underlying leukemia
o
Isolated myeloid
sarcoma: radiotherapy may result in very prolonged survival
Acute Leukemias of Ambiguous Lineage
·
Definition: acute
leukemias in which the morphologic, cytochemical and immuno-phenotypic features
of the blasts:
o Lack
sufficient evidence to classify as myeloid or lymphoid origin
o Or,
have morphologic and/or immunophenotypic characteristics of both myeloid and
lymphoid cells
o Or,
have both B and T lineages (acute bilineal leukemia and acute biphenotypic
leukemia).
·
Epidemiology: <4%
of all acute leukemias, more frequent in adults
·
Etiology: unknown,
possible causes: environmental toxins and radiation exposure
·
Clinical features
o
Related to bone
marrow failure: fatigue, infections, bleeding
·
Morphology
o
Acute undifferentiated
leukemia
§
Leukemic cells lack any differentiating features
o
Acute
biphenotypic and acute bilineal leukemias
§
May present as one subtype of AML
·
Monoblastic
·
Poorly
differentiated myeloid
§
Features of ALL
·
Immunophenotype
o
Undifferentiated
acute leukemia
§
Leukemias lack specific lineage markers
·
cCD79a, cCD22,
CD3 and MPO
§
Generally dont express more than one
lineage-associated marker
§
Often express HLA-DR, CD34, CD38, may express TdT
and CD7
o
Bilineal acute
leukemia
§
Dual population of blasts, each with distinct
lineage: positive for myeloid, lymphoid or B and T-cell markers
§
May evolve into biphenotypic acute leukemia
o
Biphenotypic
acute leukemia
§
Blasts co-express myeloid and T or B lineage
markers
§
Or, concurrent B and T lineage markers
§
Rarely co-express markers for myeloid, T and B
lineages
·
Biphenotypic
acute leukemia
o
Co-expression of one
or two cross-lineage (non specific) markers is not sufficient for biphenotypic
leukemia.
§
Myeloid-antigen positive ALL
§
Lymphoid antigen-positive AML
o
Lineage switch
after therapeutic intervention
§
Possible expansion of pre-existing minor
population of blasts of different lineage following therapeutic suppression of
the major population
§
Possible lineage instability
·
Criteria for biphenotypic leukemia: score of 2
or more for each of two separate
lineages:
o B-lymphoid:
§
Score 2: cCD79a, cIgM, cCD22
§
Score 1: CD19, CD20, CD10
§
Score 0.5: TdT, CD24
o T-lymphoid:
§
Score 2: CD3, anti-TCR
§
Score 1: CD2, CD5, CD8, CD10
§
Score 0.5: TdT, CD7, CD1a
o Myeloid:
§
Score 2: MPO
§
Score 1: CD117, CD13, CD33, CD65
§
Score 0.5: CD14, CD15, CD64
·
Differential
diagnosis
o
Biphenotypic
acute leukemia
§
Myeloid antigen positive ALL
§
Lymphoid antigen positive AML
o
Undifferentiated
acute leukemia
§
Minimally differentiated AML
§
Unusual precursor-B-cell or T-cell ALL
·
Genetics
o
High degree of
cytogenetic abnormalities
o
1/3 of cases have
Ph chromosome, these cases typically have CD10(+) precursor B lymphoid
component
o
t(4;11)(q21;q23)
or 11q23. These cases typically have CD10() precursor B lymphoid component with
a separate monocytic leukemia component
o
T/myeloid
biphenotypic or bilineal leukemia do not show cytogenetic findings listed above
but have other complex karyotypes
·
Molecular
Findings: many cases have IgH and TCR rearrangements or deletions
·
Cell of origin: multipotent
progenitor stem cell
·
Prognosis
o
Unfavorable,
particularly in adults
o
t(4;11) or Ph
particularly unfavorable
·
Therapy: usually
aggressive chemotherapy or BMT